Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice

Nobue Kitanaka, Junichi Kitanaka, F. Scott Hall, George R. Uhl, Kaname Watabe, Hitoshi Kubo, Hitoshi Takahashi, Koh Ichi Tanaka, Nobuyoshi Nishiyama, Motohiko Takemura

Research output: Contribution to journalArticle

Abstract

We investigated whether pretreatment with the neurotransmitter/ neuromodulator agmatine (decarboxylated L-arginine) affected methamphetamine (METH)-induced hyperlocomotion and stereotypy in male ICR mice. Agmatine pretreatment alone had no effects on locomotion or stereotypy, but it produced a dose-dependent attenuation of locomotion and the total incidence of stereotyped behavior induced by a low dose of METH (5 mg/kg). The stereotypy induced by this dose was predominantly characterized by stereotyped sniffing. By contrast, agmatine did not affect the total incidence of stereotypy induced by a higher dose of METH (10 mg/kg). However, the nature of stereotypy induced by this dose of METH was substantially altered; agmatine pretreatment significantly reduced stereotyped biting but significantly increased stereotyped sniffing and persistent locomotion. Agmatine pretreatment therefore appears to produce a rightward shift in the dose-response curve for METH. Pretreatment of mice with piperazine-1-carboxamidine (a putative agmatinase inhibitor) had no effect on locomotion or stereotypy induced by a low dose of METH, suggesting that endogenous agmatine may not regulate the METH action.

Original languageEnglish (US)
Pages (from-to)158-165
Number of pages8
JournalBehavioural Pharmacology
Volume25
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Agmatine
Stereotyped Behavior
Methamphetamine
Locomotion
Neurotransmitter Agents
Inbred ICR Mouse
Incidence
Arginine

Keywords

  • agmatinase inhibitor
  • agmatine
  • hyperlocomotion methamphetamine
  • mouse
  • stereotyped behavior

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Kitanaka, N., Kitanaka, J., Hall, F. S., Uhl, G. R., Watabe, K., Kubo, H., ... Takemura, M. (2014). Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice. Behavioural Pharmacology, 25(2), 158-165. https://doi.org/10.1097/FBP.0000000000000030

Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice. / Kitanaka, Nobue; Kitanaka, Junichi; Hall, F. Scott; Uhl, George R.; Watabe, Kaname; Kubo, Hitoshi; Takahashi, Hitoshi; Tanaka, Koh Ichi; Nishiyama, Nobuyoshi; Takemura, Motohiko.

In: Behavioural Pharmacology, Vol. 25, No. 2, 2014, p. 158-165.

Research output: Contribution to journalArticle

Kitanaka, N, Kitanaka, J, Hall, FS, Uhl, GR, Watabe, K, Kubo, H, Takahashi, H, Tanaka, KI, Nishiyama, N & Takemura, M 2014, 'Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice', Behavioural Pharmacology, vol. 25, no. 2, pp. 158-165. https://doi.org/10.1097/FBP.0000000000000030
Kitanaka, Nobue ; Kitanaka, Junichi ; Hall, F. Scott ; Uhl, George R. ; Watabe, Kaname ; Kubo, Hitoshi ; Takahashi, Hitoshi ; Tanaka, Koh Ichi ; Nishiyama, Nobuyoshi ; Takemura, Motohiko. / Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice. In: Behavioural Pharmacology. 2014 ; Vol. 25, No. 2. pp. 158-165.
@article{00279f0701244823b06a8aa3a6e746f3,
title = "Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice",
abstract = "We investigated whether pretreatment with the neurotransmitter/ neuromodulator agmatine (decarboxylated L-arginine) affected methamphetamine (METH)-induced hyperlocomotion and stereotypy in male ICR mice. Agmatine pretreatment alone had no effects on locomotion or stereotypy, but it produced a dose-dependent attenuation of locomotion and the total incidence of stereotyped behavior induced by a low dose of METH (5 mg/kg). The stereotypy induced by this dose was predominantly characterized by stereotyped sniffing. By contrast, agmatine did not affect the total incidence of stereotypy induced by a higher dose of METH (10 mg/kg). However, the nature of stereotypy induced by this dose of METH was substantially altered; agmatine pretreatment significantly reduced stereotyped biting but significantly increased stereotyped sniffing and persistent locomotion. Agmatine pretreatment therefore appears to produce a rightward shift in the dose-response curve for METH. Pretreatment of mice with piperazine-1-carboxamidine (a putative agmatinase inhibitor) had no effect on locomotion or stereotypy induced by a low dose of METH, suggesting that endogenous agmatine may not regulate the METH action.",
keywords = "agmatinase inhibitor, agmatine, hyperlocomotion methamphetamine, mouse, stereotyped behavior",
author = "Nobue Kitanaka and Junichi Kitanaka and Hall, {F. Scott} and Uhl, {George R.} and Kaname Watabe and Hitoshi Kubo and Hitoshi Takahashi and Tanaka, {Koh Ichi} and Nobuyoshi Nishiyama and Motohiko Takemura",
year = "2014",
doi = "10.1097/FBP.0000000000000030",
language = "English (US)",
volume = "25",
pages = "158--165",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice

AU - Kitanaka, Nobue

AU - Kitanaka, Junichi

AU - Hall, F. Scott

AU - Uhl, George R.

AU - Watabe, Kaname

AU - Kubo, Hitoshi

AU - Takahashi, Hitoshi

AU - Tanaka, Koh Ichi

AU - Nishiyama, Nobuyoshi

AU - Takemura, Motohiko

PY - 2014

Y1 - 2014

N2 - We investigated whether pretreatment with the neurotransmitter/ neuromodulator agmatine (decarboxylated L-arginine) affected methamphetamine (METH)-induced hyperlocomotion and stereotypy in male ICR mice. Agmatine pretreatment alone had no effects on locomotion or stereotypy, but it produced a dose-dependent attenuation of locomotion and the total incidence of stereotyped behavior induced by a low dose of METH (5 mg/kg). The stereotypy induced by this dose was predominantly characterized by stereotyped sniffing. By contrast, agmatine did not affect the total incidence of stereotypy induced by a higher dose of METH (10 mg/kg). However, the nature of stereotypy induced by this dose of METH was substantially altered; agmatine pretreatment significantly reduced stereotyped biting but significantly increased stereotyped sniffing and persistent locomotion. Agmatine pretreatment therefore appears to produce a rightward shift in the dose-response curve for METH. Pretreatment of mice with piperazine-1-carboxamidine (a putative agmatinase inhibitor) had no effect on locomotion or stereotypy induced by a low dose of METH, suggesting that endogenous agmatine may not regulate the METH action.

AB - We investigated whether pretreatment with the neurotransmitter/ neuromodulator agmatine (decarboxylated L-arginine) affected methamphetamine (METH)-induced hyperlocomotion and stereotypy in male ICR mice. Agmatine pretreatment alone had no effects on locomotion or stereotypy, but it produced a dose-dependent attenuation of locomotion and the total incidence of stereotyped behavior induced by a low dose of METH (5 mg/kg). The stereotypy induced by this dose was predominantly characterized by stereotyped sniffing. By contrast, agmatine did not affect the total incidence of stereotypy induced by a higher dose of METH (10 mg/kg). However, the nature of stereotypy induced by this dose of METH was substantially altered; agmatine pretreatment significantly reduced stereotyped biting but significantly increased stereotyped sniffing and persistent locomotion. Agmatine pretreatment therefore appears to produce a rightward shift in the dose-response curve for METH. Pretreatment of mice with piperazine-1-carboxamidine (a putative agmatinase inhibitor) had no effect on locomotion or stereotypy induced by a low dose of METH, suggesting that endogenous agmatine may not regulate the METH action.

KW - agmatinase inhibitor

KW - agmatine

KW - hyperlocomotion methamphetamine

KW - mouse

KW - stereotyped behavior

UR - http://www.scopus.com/inward/record.url?scp=84896405933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896405933&partnerID=8YFLogxK

U2 - 10.1097/FBP.0000000000000030

DO - 10.1097/FBP.0000000000000030

M3 - Article

VL - 25

SP - 158

EP - 165

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 2

ER -